Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Поговорим об атопическом марше у детей… Эволюция аллергии: от ринита до бронхиальной астмы
________________________________________________
Fayzullina R.M. Let's talk about atopic march allergies in children... Evolution: from rhinitis to asthma. Consilium Medicum. Pediatrics (Suppl.). 2016; 2: 70–73.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ключевые слова: атопический марш, аллергические заболевания у детей, аллергический ринит, атопический дерматит, антилейкотриеновые препараты, интраназальные глюкокортикостероиды, будесонид, монтелукаст.
________________________________________________
The widely used term "atopic march" confirms the evolving nature of current allergy: making his debut as a child, this pathology accompanies the patient throughout their lives. Atopic march is the natural course of the manifestations of atopic heredity child. Atopic dermatitis (AD), allergic rhinitis (AR) and bronchial asthma (BA) are three interrelated diseases not only in its pathologic basis and mechanisms of development. Most of the patients they are transformed into each other or together. Timely diagnosis of atopy in the child and adequate therapy of AD and AR contributed to the prevention of severe forms of the disease, and progression of atopic disease (atopic march). In chronic allergic inflammation in the upper airways accompanying AP, the most effective is the use of topical intranasal glucocorticosteroid drugs (e.g. budesonide), which is currently widely prescribed in clinical practice due to its high efficiency and lack of complications in their correct use. Antileukotriene drugs, in particular drug montelukast, appointed for prevention and long-term treatment of asthma and AR to prevent daytime and nighttime asthma attacks in aspirin-sensitive patients acid, prevention of bronchospasm caused by exercise-induced and acute respiratory viral infection. Inclusion in the montelukast therapy program for children with recurrent acute respiratory AP, is especially important as a preventive treatment of respiratory allergies.
Key words: atopic march, allergic diseases in children, allergic rhinitis, atopic dermatitis, antileukotriene preparations, intranasal corticosteroids, budesonide, montelukast.
2. Пыцкий В.И. и др. Аллергические заболевания. М.: Медицина, 1991. / Pytskii V.I. i dr. Allergicheskie zabolevaniia. M.: Meditsina, 1991. [in Russian]
3. Аллергология и иммунология. Под общ. ред. А.А.Баранова, Р.М.Хаитова. М., 2010; с. 36. / Allergologiia i immunologiia. Pod obshch. red. A.A.Baranova, R.M.Khaitova. M., 2010; s. 36. [in Russian]
4. Кондюрина Е.Г., Зеленская В.В., Елкина Т.Н. и др. Роль терапии атопического дерматита в профилактике атопического марша, Педиатрия. 2005; 1 (4): 26–30. / Kondiurina E.G., Zelenskaia V.V., Elkina T.N. i dr. Rol' terapii atopicheskogo dermatita v profilaktike atopicheskogo marsha, Pediatriia. 2005; 1 (4): 26–30. [in Russian]
5. Новик Г.А., Вишнева Е.А., Намазова-Баранова Л.С. Приверженность: роль в достижении контроля над бронхиальной астмой у детей. Педиатрическая фармакология. 2015; 12 (2): 190–6. / Novik G.A., Vishneva E.A., Namazova-Baranova L.S. Priverzhennost': rol' v dostizhenii kontrolia nad bronkhial'noi astmoi u detei. Pediatricheskaia farmakologiia. 2015; 12 (2): 190–6. [in Russian]
6. Булгакова В.А., Балаболкин И.И. Сочетанные проявления респираторной и кожной аллергии у детей. Мед. совет. 2008; 5–6. / Bulgakova V.A., Balabolkin I.I. Sochetannye proiavleniia respiratornoi i kozhnoi allergii u detei. Med. sovet. 2008; 5–6. [in Russian]
7. Miller-Larsson A et al. Prolonged Airway Activity and Improved Selectivity of Budesonide Possibly Due to Esterification. Am J Respir Crit Care Med 2000; 162: 1455–61.
8. Геппе Н.А., Фролкова Е.В. Монтелукаст – антагонист лейкотриеновых рецепторов в терапии бронхиальной астмы у детей. Доктор.Ру. Пульмонология. 2013; 8 (86): 3–6. / Geppe N.A., Frolkova E.V.. Montelukast – antagonist leikotrienovykh retseptorov v terapii bronkhial'noi astmy u detei. Doktor.Ru. Pul'monologiia. 2013; 8 (86): 3–6. [in Russian]
________________________________________________
1. Allergiia u detei: ot teorii – k praktike. Pod red. L.S.Namazovoi-Baranovoi. M., 2010–2011. [in Russian]
2. Pytskii V.I. i dr. Allergicheskie zabolevaniia. M.: Meditsina, 1991. [in Russian]
3. Allergologiia i immunologiia. Pod obshch. red. A.A.Baranova, R.M.Khaitova. M., 2010; s. 36. [in Russian]
4. Kondiurina E.G., Zelenskaia V.V., Elkina T.N. i dr. Rol' terapii atopicheskogo dermatita v profilaktike atopicheskogo marsha, Pediatriia. 2005; 1 (4): 26–30. [in Russian]
5. Novik G.A., Vishneva E.A., Namazova-Baranova L.S. Priverzhennost': rol' v dostizhenii kontrolia nad bronkhial'noi astmoi u detei. Pediatricheskaia farmakologiia. 2015; 12 (2): 190–6. [in Russian]
6. Bulgakova V.A., Balabolkin I.I. Sochetannye proiavleniia respiratornoi i kozhnoi allergii u detei. Med. sovet. 2008; 5–6. [in Russian]
7. Miller-Larsson A et al. Prolonged Airway Activity and Improved Selectivity of Budesonide Possibly Due to Esterification. Am J Respir Crit Care Med 2000; 162: 1455–61.
8. Geppe N.A., Frolkova E.V.. Montelukast – antagonist leikotrienovykh retseptorov v terapii bronkhial'noi astmy u detei. Doktor.Ru. Pul'monologiia. 2013; 8 (86): 3–6. [in Russian]
ГБОУ ВПО Башкирский государственный медицинский университет Минздрава России. 450008, Россия, Уфа, ул. Ленина, д. 3
*fayzullina@yandex.ru
________________________________________________
R.M.Fayzullina*
Bashkir State Medical University of the Ministry of Health of the Russian Federation. 450008, Russian Federation, Ufa, ul. Lenina, d. 3
*fayzullina@yandex.ru